Pharmacokinetics of sisomicin in patients with normal and impaired renal function; its efficacy in urinary tract infection
- PMID: 789084
- DOI: 10.1007/BF00565626
Pharmacokinetics of sisomicin in patients with normal and impaired renal function; its efficacy in urinary tract infection
Abstract
Serum concentration, biological half-life, distribution space and serum clearance of sisomicin, a new aminoglycoside antibiotic, have been studied in twenty-three patients in comparison with the pharmacokinetics of 125I-labelled iothalamate, a compound only filtered by the kidney. 10 patients had normal or borderline abnormal serum creatinine (less than 1,5 mg/100 ml), 8 had various degrees of renal insufficiency (serum creatinine 1.7-9.6 mg/100 ml) and 6 were being treated by intermittent haemodialysis. After intravenous injection of sisomicin 1 mg/kg body weight in patients with normal or borderline renal function its half-life was 3.5 h, very similar to that of iothalamate, 3.2 h. The mean distribution space was 20.1% per cent of body weight; iothalamate, 23.7%. In patients with renal insufficiency there was a positive correlation between serum creatinine level and the half-life of sisomicin, and an even stronger correlation between the clearances of iothalamate and sisomicin. In patients dependent on haemodialysis, the mean serum half-life between dialysis was 40 h, compared to approximately 100 hours for iothalamate, which implies additional extrarenal clearance or tubular secretion of sisomicin. The results of pharmacokinetic studies indicated that a regime of sisomicin 1 mg/kg every 8 to 12 hours in patients with normal renal function would result in serum and urine levels sufficiently high to treat most urinary tract infections. In patients with impaired renal function the dosage interval should be increased according to the serum creatinine level, and in patients dependent on haemodialysis one standard dose at the end of each dialysis period should suffice. 9 patients with a chronic urinary tract infection severely complicated by an underlying disease were treated according to this dosage regimen with a satisfactory bacteriological and clinical result. No adverse reactions or signs of accumulation were observed.
Similar articles
-
Treatment with sisomicin of complicated urinary tract infections in patients with varying degrees of renal function impairment, pharmacokinetics and dosage adjustment.Infection. 1975;3(3):143-7. doi: 10.1007/BF01641336. Infection. 1975. PMID: 1223005
-
[Pharmacokinetics and clinical observations of sisomicin, a newly developed aminoglycoside derivative (author's transl)].Dtsch Med Wochenschr. 1975 Oct 17;100(42):2144-50. doi: 10.1055/s-0028-1106513. Dtsch Med Wochenschr. 1975. PMID: 1164890 Clinical Trial. German.
-
Clinical pharmacokinetics of sisomicin: dosage schedules in renal-impaired patients.Antimicrob Agents Chemother. 1976 May;9(5):761-5. doi: 10.1128/AAC.9.5.761. Antimicrob Agents Chemother. 1976. PMID: 986124 Free PMC article.
-
Plazomicin: an investigational therapy for the treatment of urinary tract infections.Expert Opin Investig Drugs. 2015;24(11):1501-11. doi: 10.1517/13543784.2015.1095180. Epub 2015 Sep 30. Expert Opin Investig Drugs. 2015. PMID: 26419762 Review.
-
Pharmacokinetics of aminoglycosides in subjects with normal and impaired renal function.Antibiot Chemother (1971). 1978;25:163-80. doi: 10.1159/000401061. Antibiot Chemother (1971). 1978. PMID: 352252 Review.
Cited by
-
Measured Glomerular Filtration Rate: The Query for a Workable Golden Standard Technique.J Pers Med. 2021 Sep 24;11(10):949. doi: 10.3390/jpm11100949. J Pers Med. 2021. PMID: 34683089 Free PMC article. Review.
-
Drug kinetics and artificial kidneys.Clin Pharmacokinet. 1977 Nov-Dec;2(6):403-26. doi: 10.2165/00003088-197702060-00002. Clin Pharmacokinet. 1977. PMID: 22417
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources